Iovance Biotherapeutics

Valuation Analysis

About the Company

Iovance Biotherapeutics en bref

Iovance Biotherapeutics (IOVA) is currently trading at 3,53 € with a market capitalization of 1,6 Md €. The 52-week range spans from 1,53 € to 4,89 €; the current price is 27.8% below the yearly high. Year-over-year revenue growth stands at +44.8%.

💰 Dividende

Iovance Biotherapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

9 analystes évaluent Iovance Biotherapeutics (IOVA) au consensus : Acheter. L'objectif de cours moyen est de 7,13 €, soit un potentiel de +102.02% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 3,47 € à 12,14 €.

Iovance Biotherapeutics : la thèse d'investissement en détail

Iovance Biotherapeutics (IOVA) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Top-line momentum is unusually strong with revenue expanding 44.8% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. Wall Street consensus sits at Buy with an average price target implying roughly 102.02% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 23.95% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

À surveiller

• The analyst consensus price target implies 102.02% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (23.95%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Iovance Biotherapeutics?

Compare top-rated brokers — low fees, trusted providers, fully regulated.